Medpace Insider Trade: CEO Troendle Offloads $22M in Stock

Rhea-AI Filing Summary

Medpace Holdings (MEDP) – Form 4 insider transaction

CEO, Chairman and 10% owner August J. Troendle sold 48,487 common shares on 28-Jul-2025 at a weighted-average price of $451.69 (range $450.00-$454.96), yielding roughly $21.9 million in proceeds. The sale was executed via a limit order during an open trading window.

After the sale, Troendle still controls 962,615 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC—about 5.7 million shares in total—so his overall influence remains substantial. No derivative transactions were reported.

The transaction trims his direct stake by ~5%, but does not materially alter insider ownership or governance dynamics.

Positive

• CEO retains approximately 5.7 million shares, preserving strong alignment with shareholder interests
• Transaction executed within open window via limit order, reflecting adherence to compliance best practices

Negative

• Sale of 48,487 shares (~$21.9 m) by CEO may be interpreted as reduced confidence or desire to diversify personal holdings

Insights

Financial Analyst

TL;DR: CEO sold ~48k shares (~$22 m); ownership still strong; mildly negative sentiment due to reduced direct stake.

The sale represents roughly 5% of Mr. Troendle’s direct holdings and less than 1% of his total economic exposure when including the 4.7 million shares held via Medpace Investors, LLC. While insider disposals can signal caution, the remaining stake indicates continued alignment with shareholders. No options were exercised, suggesting the sale was liquidity-driven rather than hedging against expected downside. Given MEDP’s ~$13 bn market cap, the dollar amount is immaterial to valuation but may create short-term pressure on sentiment.

Corporate Governance Specialist

TL;DR: Insider sale reduces direct ownership but leaves control position intact; governance risk unchanged.

Troendle remains both CEO and controlling unitholder of Medpace Investors, LLC, so effective voting power is preserved. The use of a window-period limit order complies with insider-trading best practices, reducing compliance risk. Investors should monitor future sales patterns for any acceleration that could indicate shifting commitment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/28/2025		S(1)		48,487	D	$451.69(2)	962,615	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $450.00 to $454.96. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	07/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MEDP shares did CEO August J. Troendle sell?

He sold 48,487 common shares on 28-Jul-2025.

What price did the MEDP insider shares sell for?

The weighted-average sale price was $451.69, within a $450.00–$454.96 range.

How many MEDP shares does the CEO still own after the sale?

He owns 962,615 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC.

Did the Form 4 report any derivative transactions for MEDP?

No, no derivative securities were acquired or disposed of in this filing.

Does this insider sale materially affect CEO control of MEDP?

No; despite the sale, the CEO still controls about 5.7 million shares, maintaining significant voting power.